Table 3.
Parasite | Infection/Life Stage/Antigen | Host/Location/Model | Effect on NF-κB | Outcome |
---|---|---|---|---|
T. gondii [82] |
|
Mouse primary peritoneal macrophages | Phosphorylation of p65 through downregulation of miR-187. | Delayed production of IL-12. |
T. gondii [87] |
|
Human Non-Small Cell Lung Cancer H1299 cells deficient in p53 | GRA16 prevents NF-κB activation; decreased total and nuclear levels of p65, decreased IKKβ level, decreased phosphorylation of IkBα. | Decrease in cell survival, induce cell apoptosis. |
T. gondii [86] |
|
Human neutrophils | Reduction in LPS-induced IκBα degradation and p65 phosphorylation. | Reduction in release of LPS induced IL-1β. |
T. gondii [88] |
|
In vivo: mice. In vitro: bone marrow derived macrophages, RAW 264.7, adherent peritoneal macrophages, HELA cells |
Virulent strain resulted in less p65 translocation to the nucleus and IκBα phosphorylation compared to avirulent strain. | Avirulent strains induced increased TNF-α and IL-12 release compared to virulent strains. Avirulent and virulent strain polarized macrophages towards M1 and M2 phenotypes, respectively. |
T. gondii [89] |
|
Human foreskin fibroblasts, NIH 3T3 fibroblasts, MEF, HeLa, and COS cell lines, as well as primary cultures of mouse and human macrophages | Lack of nuclear p65/RelA translocation despite IκB degradation. No increase in expression of NF-κB dependent genes upon infection. | The results show that T. gondi may use undefined mechanisms to interfere with NF-κB signaling. |
T. gondii [84] |
|
Mouse bone marrow-derived macrophages | Inhibition of LPS-induced NF-κB translocation. | Blocked production of proinflammatory TNF-α and delayed (24 h) IL-12 in response to LPS. |
T. gondii [81] |
|
In vivo: mice. In vitro: mouse bone marrow derived macrophages |
In vivo: activation of NF-κB, higher expression of p65, p50 from 24 h. In vitro: no p65 and cRel translocation to nucleus. |
In vitro: reduced capacity to increase transcription of IL-12, IL-18, and iNOS in response to LPS and IFN-γ. |
T. gondii [90] |
|
3T3 mouse embryonic fibroblasts, 3T3 p65−/− fibroblasts | nuclear translocation of p50 and p65. Higher affinity to DNA for p50, p52, p65, and RelB. Phosphorylation but no IκB degradation. | Upregulation of antiapoptotic responses. |
T. gondii [91] |
|
Human foreskin fibroblast, RAW264.7 (mouse macrophage cell line), U937 (human macrophage cell line) | ROP18+ strain induced p65 phosphorylation at Ser468 and promotes its degradation. | ROP18+: reduced LPS-induced IL-6, IL-12, and TNF-α; M2-biased phenotypes. ROP18-: enhanced LPS-induced IL-6, IL-12, and TNF-α; M1-biased activation. This strain has a relative inability to inhibit the NF-κB pathway. |
T. gondii [92] |
|
Mouse bone marrow-derived macrophages | No change in LPS induced p65 accumulation in nucleus as well as NF-kB binding to DNA. Significant diminished ability of p65 to bind to TNF-α promoter. | Describes T. gondi’s ability to interfere with TNF-α transcription. |
T. gondii [74] |
|
Primary human monocytes and THP-1 cells | Type II: increased p65 accumulation in nucleus. | Type II: expression of IL-1β. |
T. gondii [85] |
|
Primary human peripheral blood monocytes | Increase in phosphorylation of p65. | Expression of IL-1β. |
T. gondii [80] |
|
Wild type and RelB−/− C57B6 mice. | Infection induces NF-κB DNA binding activities of p65 and RelB containing complexes in the spleen. | RelB−/− mice show high mortality in response to the infection with negligible levels of IFN-γ and diminished NK cell activity. |
T. gondii [83] |
|
In vivo: Mice (injected intra peritoneally with tachyzoites). In vitro: mouse peritoneal macrophages macrophage cell lines (RAW 264.7 and THP-1) |
In vivo: no NF-κB translocation in macrophages or neutrophils within 4h of infection. In vitro: rapid IκB phosphorylation and degradation but NF-κB p50-p65 heterodimers did not translocate to the nucleus. |
In vitro: little or no production of IL-12 and TNF-α; LPS triggering unable to promote IL-12 and TNF-α production. |